---
document_datetime: 2024-09-05 10:24:39
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nordimet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: nordimet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.1237736
conversion_datetime: 2025-12-29 19:26:43.458435
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nordimet

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                     |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2014/ 202310   | Periodic Safety Update EU Single assessment - methotrexate                                                                                   | 27/06/2024                          | 30/08/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2014/202310.                                                                                   |
| II/0033/G            | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation | 08/02/2024                          | 30/08/2024                                  | PL                               | Section 6 of Package Leaflet is being updated to include the new proposed drug product batch release site Sever Pharma Solutions AB for the finished product Nordimet 25 mg/ml solution for injection in pre-filled syringe |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                 |            |            |                 | (EU/1/16/1124/025-056).                                                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------|
| II/0027   | Extension of indication to include treatment of moderate psoriasis in adults who are candidates for systemic therapy based on literature; As a consequence, sections 4.1, 4.2 and 4.9 of the SmPC were updated. The Package leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 14/09/2023 | 18/10/2023 | SmPC and PL     | Please refer to Scientific Discussion Nordimet EMEA/H/C/003983/II/0027 |
| IAIN/0032 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/10/2023 | 30/08/2024 | Annex II and PL |                                                                        |
| IB/0031/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                        | 28/09/2023 | n/a        |                 |                                                                        |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                         |            |            |                     |                                                                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|--------------------------------------------------------------------------------|
| IB/0030            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                              | 30/03/2023 | 18/10/2023 | SmPC and PL         |                                                                                |
| N/0028             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                            | 13/03/2023 | 18/10/2023 | Labelling and PL    |                                                                                |
| N/0029             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                            | 02/03/2023 | 18/10/2023 | PL                  |                                                                                |
| IAIN/0026/G        | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 23/08/2022 | 28/11/2022 | Annex II and PL     |                                                                                |
| PSUSA/2014/ 202110 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                  | 10/06/2022 | n/a        |                     | PRAC Recommendation - maintenance                                              |
| IB/0024            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                              | 24/02/2022 | 28/11/2022 | SmPC and PL         | Update of Section 4.4 of the SmPC with revised wording on liver function tests |
| IB/0022            | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                    | 13/01/2022 | 28/11/2022 | SmPC, Labelling and |                                                                                |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0023 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/12/2021 | 28/11/2022 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0018    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/04/2021 | 21/06/2021 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Nordimet in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Section 4.5 of the SmPC has been updated based on literature reference data to add information on the concomitant use of methotrexate and cyclosporin: 'Cyclosporine may potentiate methotrexate efficacy and toxicity. There is an increased risk of renal dysfunction. In addition, there is a biological plausibility of excessive |
| IB/0019/G | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation | 27/01/2021 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                    | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016            | Extension of Indication to include the new indication 'Induction of remission in moderate steroid- dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate' for Nordimet; as a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 5.3 has been adopted. The MAH took the opportunity to update the RMP with changes related to GVP V version 2 template and the outcome of MTX referral. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 10/12/2020 | 21/01/2021 | SmPC and PL            | Please refer to the Scientific Discussion Nordimet EMEA/H/C/003983/II/0016                                                                                                         |
| PSUSA/2014/ 201910 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/05/2020 | 23/07/2020 | SmPC and PL            | Please refer to Jylamvo - Nordimet EMEA/H/C/PSUSA/00002014/201910 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IAIN/0015/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/12/2019 | 23/07/2020 | SmPC, Labelling and PL |                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|          | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                              |                                                                                                                   |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IA/0014  | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/11/2019 | n/a        |                              |                                                                                                                   |
| A31/0006 | Pursuant to Article 31 of Directive 2001/83/EC, Spain requested on 22 March 2018 the opinion of the European Medicines Agency further to serious cases of overdose, sometimes fatal, having been reported in patients inadvertently receiving the product daily instead of weekly for indications that require weekly dosing despite additional risk minimisation measures having been put in place by several Member States. The CHMP was requested to assess the impact thereof on the benefit-risk balance of methotrexate- containing medicinal products and to give its recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC). | 22/08/2019 | 17/10/2019 | SmPC, Annex II and Labelling | Please refer to the assessment report: Jylamvo EMEA/H/A-31/1463/C/3756/0002 Nordimet EMEA/H/A-31/1463/C/3983/0006 |

<div style=\"page-break-after: always\"></div>

| IB/0013            | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/09/2019   | n/a        |                        |                                                                                                                                                                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2014/ 201810 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/06/2019   | 23/08/2019 | SmPC and PL            | Please refer to Jylamvo - Nordimet EMEA/H/C/PSUSA/00002014/201810 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0012/G          | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within | 17/04/2019   | 23/08/2019 | SmPC, Labelling and PL |                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| B.II.e.5.a.1 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.2 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.2 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.2 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.2 - Change in product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.2 - Change in product - Change in the etc.)   | tablets, ampoules,   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|

<div style=\"page-break-after: always\"></div>

|           | - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the currently approved pack sizes                                                                                                                                                                                                                                                                                  |            |            |                        | B.II.e.5.a.2 the range of   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------|
| IB/0010/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 18/12/2018 | 25/03/2019 | SmPC, Labelling and PL |                             |

<div style=\"page-break-after: always\"></div>

|                    | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |            |            |             |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0009            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/11/2018 | n/a        |             |                                                                                                                                           |
| IB/0008            | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/05/2018 | n/a        |             |                                                                                                                                           |
| PSUSA/2014/ 201706 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/03/2018 | 16/05/2018 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2014/201706. |
| IAIN/0007          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/04/2018 | 25/03/2019 | SmPC and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0005   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/12/2017   | n/a        |                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IB/0003/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. | 16/09/2017   | 16/05/2018 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within

<div style=\"page-break-after: always\"></div>

| the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the currently approved pack sizes - Change in any part of the (primary) material not in contact with the finished formulation - Change that affects the information - Administrative change - Change in ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        | the range of B.II.e.6.a packaging product product A.6 Code/ATC   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------|
| IB/0002/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes Change in pack size of the finished | 11/10/2016 | 07/08/2017 | SmPC, Labelling and PL | B.II.e.5.a.2 - product - Change                                  |

<div style=\"page-break-after: always\"></div>

tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.

<div style=\"page-break-after: always\"></div>

|             | tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                               | 15/09/2016 | 07/08/2017 | Annex II and PL |